静脉氨甲环酸安全有效地降低翻修全髋关节置换术中的输血率
该回顾性研究纳入2005年至2014年间3264例翻修全髋关节置换术(THA),其中1142例接受静脉氨甲环酸(TXA)治疗。结果显示,TXA显著降低总体输血率(54%降至26%,p<0.001),无菌性和感染性翻修亚组均显著降低;有症状静脉血栓栓塞事件(VTE)率在两组间无显著差异。
要点
- 静脉TXA使翻修THA总体输血率从54%降至26%(p<0.001;校正RR 1.6;95%CI 1.3-1.9)。
- 无菌性翻修输血率从49%降至18%(p<0.001),感染性翻修从73%降至53%(p=0.04)。
- VTE发生率低,TXA组3例(0.3%),非TXA组4例(0.2%),无显著差异。
核心结论
- 静脉TXA显著降低全因翻修THA的输血率,包括无菌性和感染性翻修亚组;倾向性评分校正后两组VTE率无统计学差异。
研究设计与样本
- 回顾性研究,纳入2005年至2014年间3264例翻修THA(2645例患者),其中1142例接受静脉TXA(切皮时1g,关闭切口时1g)。
- 采用倾向性评分最小化组间偏倚,纳入变量包括翻修时年龄、性别、体重指数、美国麻醉医师协会(ASA)评分、术前抗凝和手术年份。
主要发现
- TXA组平均年龄65岁(28至95),女性579例(51%);非TXA组平均年龄67岁(21至98),女性1160例(55%)。
- 总体输血率从54%降至26%(p<0.001;校正相对危险度(RR)1.6;95%置信区间(CI)1.3至1.9)。
- 无菌性翻修输血率从49%降至18%(p<0.001);感染性翻修从73%降至53%(p=0.04)。
- VTE发生率总体很低,TXA组3例(0.3%),非TXA组4例(0.2%);基于TXA使用或翻修病因,VTE率无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Tranexamic acid (TXA) has been shown to significantly reduce transfusion rates in primary total hip arthroplasties (THAs), but high-quality evidence is limited in the revision setting. The purpose of the current study was to compare the rate of blood transfusions and symptomatic venous thromboembolic events (VTEs) in a large cohort of revision THAs treated with or without intravenous (IV) TXA. PATIENTS AND METHODS: We performed a retrospective review of 3264 revision THAs (2645 patients) between 2005 and 2014, of which 1142 procedures received IV TXA (1 g at incision and 1 g at closure). The mean age in the revision group with TXA was 65 years (28 to 95), with 579 female patients (51%). The mean age in the revision group treated without TXA was 67 years (21 to 98), with 1160 female patients (55%). Outcomes analyzed included rates of transfusion and symptomatic VTEs between procedures undertaken with and without TXA. These comparisons were performed for the overall cohort, as well as within cases subcategorized for aseptic or septic aetiologies. A propensity score was developed to minimize bias between groups and utilized age at revision THA, sex, body mass index, American Society of Anesthesiologists (ASA) score, preoperative anticoagulation, and year of surgery. RESULTS: Tranexamic acid significantly and substantially reduced the rate of blood transfusions after revision THA overall from 54% to 26% (p < 0.001; adjusted relative risk (RR) 1.6; 95% confidence interval (CI) 1.3 to 1.9), with a significant reduction in both aseptic (49% to 18%; p < 0.001) and septic (73% to 53%; p = 0.04) revisions. The rate of VTE was minimal overall, with three events (0.3%) in the TXA group and four events (0.2%) in the non-TXA group. There were no significant differences in VTE rates based on TXA use or aetiology of revision. CONCLUSION: Intravenous TXA significantly reduced transfusion rates during all-cause revision THAs, including a subgroup analysis of both aseptic and septic cohorts. Adjusted risk using propensity modelling showed no statistical difference in rates of VTEs between either group. Cite this article: Bone Joint J 2019;100-B(6 Supple B):104-109.
引用
- Hines JT, Hernandez NM, Amundson AW, et al. Intravenous tranexamic acid safely and effectively reduces transfusion rates in revision total hip arthroplasty. Bone Joint J. 2019. PMID: 31146563. doi:10.1302/0301-620X.101B6.BJJ-2018-1376.R1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。